Press Releases

London, England, May 15, 2024 (GLOBE NEWSWIRE) -- Democratic nations tended to fare better during the pandemic with fewer excess deaths than autocratic nations, according to new analysis by Airfinity.

Today’s analysis is being presented at the Copenhagen Democracy Summit by Airfinity’s CEO and founder Rasmus Bech Hansen. It shows that for the vast majority of countries, strong democratic government was a key predictor of lower excess deaths during the... (continue reading...)

TEL AVIV, Israel--(BUSINESS WIRE)-- oceansix future paths Ltd. (“oceansix” or the “Company”), a leader in advanced recycling and manufacturing technological solutions with a presence on the TSX Venture Exchange in Toronto (TSXV: CUSIP 001194828, OSIX), in New York (OTCQB: AKMYF), and Frankfurt Stock Exchange (WKN: A3EFB0, ISIN: IL0011948283, 5FC0), is pleased to announce that today it has entered into an asset purchase agreement (the “Agreement”)... (continue reading...)

--Third-generation haptics offer crisp tactile feedback to drivers, enhancing safety

BROMONT, Québec--(BUSINESS WIRE)-- Boréas Technologies — a pioneer in third-generation, piezo-based haptics for automotive, consumer and mobile applications — has completed AEC-Q100 Grade 2 qualification for the BOS1211, its powerful piezo haptic driver IC designed for the automotive market.

This press release features multimedia. View the full release here: ... (continue reading...)

New Phase 3 data evaluating sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed antibody-drug conjugate, in previously treated locally recurrent or metastatic triple-negative breast cancer

First presentation of Phase 2b three-year follow-up data evaluating mRNA-4157 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk stage III/IV melanoma following complete... (continue reading...)

FRANKLIN LAKES, N.J., May 15, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced U.S. Food and Drug Administration (FDA) approval for the use of self-collected vaginal specimens for human papillomavirus (HPV) testing when cervical specimens cannot otherwise be obtained. The approval allows women to self-collect vaginal specimens for HPV testing in a health care setting, which could include... (continue reading...)